The nephrotoxicity of ceftazidime compared with that of cefazolin or cephaloridine and the capacity of ceftazidime to enhance the nephrotoxicity of tobramycin were evaluated in rats. Only cephaloridine and tobramycin given alone altered creatinine clearance or caused significant histological injury. Our data suggest that ceftazidime is no more nephrotoxic than cefazolin and does not enhance the nephrotoxicity of tobramycin.
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removed, rapidly transferred to Formalin-containing vials, embedded in paraffin, stained with hematoxylin-eosin, coded, and read by one of us (D.W.V.) who was unaware of the regimens. In the grading system, cloudy swelling, round cell infiltration, interstitial fibrosis, tubular dilation, and tubular necrosis were considered. These features were assigned scores of 1 through 4 according to the percentage of the renal cortex involved, i.e., 25, 50, 75, or 100%. Statistical evaluation consisted of two-way analysis of variance for the continuous variables and the Kendall-Tau nonparametric test for the histological scores. Data are expressed as mean + standard error. The 95% limits of probability were accepted as significant.
Data obtained at sacrifice are given in Table 1 . As indicated, cefazolin and cephaloridine caused dose-related decreases in urine osmolality. Ceftazidime, when given concurrently with tobramycin, actually decreased urinary protein excretion. Because of the relatively minor degree of toxicity exhibited by the regimens and because of the variability in creatinine clearance measurements, no interaction between the creatinine clearances and the regimens was identified by analysis of variance. When the serum creatinine determinations were analyzed separately, however, significant differences were identified. The change in creatinine, determined by subtracting the value at sacrifice from the value at entry for each animal, is given in Table 1 . Increasing doses of cephaloridine caused a significant increase in serum creatinine (high dose > middle dose = low dose). Adding ceftazidime to tobramycin actually decreased changes in creatinine incrementally (tobramycin alone > tobramycin + ceftazidime at low dose > tobramycin + ceftazidime middle dose = tobramycin + ceftazidime at high dose). The pathological scores show that only cephaloridine and tobramycin in high doses caused nephrotoxicity. The changes evoked by tobramycin were ameliorated by ceftazidime in a dose-related fashion.
This study shows that ceftazidime is not nephrotoxic to rats. In this regard, ceftazidime appears to be similar to cefazolin, a drug with a record of being well tolerated. On the other hand, ceftazidime is clearly less toxic than cephaloridine, which was included as a positive control. Tobramycin caused renal damage, as has been previously described for this aminoglycoside (6) . Because it was concluded in a prospective double-blind trial in humans that the combination of cephalothin and an aminoglycoside was more nephrotoxic than was methicillin plus an aminoglycoside (8), we studied ceftazidime given concomitantly with tobramycin. Rather than augmenting nephrotoxicity, ceftazidime exerted an ameliorative effect. A similar effect has been reported in ANTIMICROB. AGENTS CHEMOTHER. rats receiving other combinations of ,B-lactam antibiotics combined with aminoglycosides (5). The mechanisms behind these anomolous results are unknown; however, recent results from this laboratory have demonstrated that in humans the ,-lactam antibiotic moxalactam decreases the halflife of tobramycin in plasma (1). Thus, it is possible that 1B-lactam antibiotics facilitate the elimination of aminoglycosides from the body. In this regard, the findings suggesting that cephalothin increases aminoglycoside nephrotoxicity may be explained by variable degrees of protection, since no aminoglycoside alone group was included in that human study (8) . In conclusion, ceftazidime compares favorably with other cephalosporins with respect to nephrotoxicity in rats. In this animal model, ceftazidime ameliorates aminoglycoside nephrotoxicity.
